|
28 Oct 2019 |
Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer
|
|
28 Oct 2019 |
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
|
|
28 Oct 2019 |
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
|
|
28 Oct 2019 |
Y-mAbs Announces Positive Omburtamab Clinical Data
|
|
28 Oct 2019 |
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
|
|
28 Oct 2019 |
Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference
|
|
28 Oct 2019 |
Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
|
|
28 Oct 2019 |
Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar candidate FYB202
|
|
27 Oct 2019 |
Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
|
|
25 Oct 2019 |
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
|
|
25 Oct 2019 |
Y-mAbs Announces Naxitamab Update
|
|
25 Oct 2019 |
European Commission Approves Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
|
|
24 Oct 2019 |
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
|
|
24 Oct 2019 |
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
|
|
24 Oct 2019 |
Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis
|
|
23 Oct 2019 |
Janssen Seeks to Expand Use of TREMFYA (guselkumab) in the Treatment of Adults With Active Psoriatic Arthritis
|
|
22 Oct 2019 |
Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma
|
|
22 Oct 2019 |
CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer
|
|
22 Oct 2019 |
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
|
|
22 Oct 2019 |
Aslan Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting atopic dermatitis
|
|
21 Oct 2019 |
Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
|
|
21 Oct 2019 |
New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive Phase 1 results for the treatment of IBD in data presented at UEG Week Barcelona 2019
|
|
21 Oct 2019 |
Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board
|
|
21 Oct 2019 |
Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-Free Survival in People With Unresectable Hepatocellular Carcinoma
|
|
19 Oct 2019 |
Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)
|
